Directed evolution expands CRISPR–Cas12a genome-editing capacity

Authors:

Abstract
CRISPR–Cas12a enzymes are versatile RNA-guided genome-editing tools with applications encompassing viral diagnosis, agriculture, and human therapeutics. However, their dependence on a 5′-TTTV-3′ protospacer adjacent motif (PAM) next to DNA target sequences restricts Cas12a’s gene targeting capability to only ∼1% of a typical genome. To mitigate this constraint, we used a bacterial-based directed evolution assay combined with rational engineering to identify variants of Lachnospiraceae bacterium Cas12a with expanded PAM recognition. The resulting Cas12a variants use a range of noncanonical PAMs while retaining recognition of the canonical 5′-TTTV-3′ PAM. In particular, biochemical and cell-based assays show that the variant Flex-Cas12a utilizes 5′-NYHV-3′ PAMs that expand DNA recognition sites to ∼25% of the human genome. With enhanced targeting versatility, Flex-Cas12a unlocks access to previously inaccessible genomic loci, providing new opportunities for both therapeutic and agricultural genome engineering.
All Related Versions
Funding Information
  • Life Sciences Research Foundation
  • Rett Syndrome Research Trust
  • The Jane Coffin Childs Fund for Medical Research
  • Howard Hughes Medical Institute
  • NIH (U01AI142817)
  • NIAID (U19AI171110, U54AI170792, U19AI135990, UH3AI150552, U19NS132303)
  • NHLBI (R21HL173710)
  • NSF (2334028)
  • DOE (DE-AC02-05CH11231, 2553571, B656358)
  • Lawrence Livermore National Laboratory (24180)
  • CB-Hampton University Summer Program
  • Mr Li Ka Shing
  • Koret-Berkeley-TAU
  • Emerson Collective
  • Innovative Genomics Institute